DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

DBV Technologies announced the first participant has been screened in the THRIVE Phase 2 clinical study evaluating the efficacy and safety of the VIASKIN® Peanut Patch in infants ages 6-12 months with peanut allergy. The study will assess whether the patch can enable ad lib (unrestricted) peanut consumption through epicutaneous immunotherapy (EPIT), building on positive results from earlier trials in older age groups.